Monday, July 9, 2012
Caliper Life Sciences, a provider of tools and services for drug
discovery and life sciences research, has launched a new services
offering based on a panel of cellular assays that measure the effects of
drug candidates on functional activity of proteins called kinases involved
in critical cell-signaling pathways. The technology platform and initial
panel of nine assays were developed in collaboration with Pfizer. The new offering, called In-Cell KinaseScreen, is immediately available for compound screening, profiling, and custom assay development services for CDAS’ clients, ranging from academia to pharmaceutical companies.